The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights Cash and cash ...

(Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample ...

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest More than 10 loss-making biotechnology companies have filed for ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

Scientists recorded 24 hours of the cellular construction process, revealing surprising new details about how plant cell ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Political attacks on teaching about gender in colleges and universities are about more than just gender: They are part of a ...